Potent Anti-HIV Chemokine Analogs Direct Post-Endocytic Sorting of CCR5

被引:15
|
作者
Boensch, Claudia [1 ]
Munteanu, Mihaela [1 ]
Rossitto-Borlat, Irene [1 ]
Fuerstenberg, Alexandre [2 ]
Hartley, Oliver [1 ]
机构
[1] Univ Geneva, Dept Pathol & Immunol, Fac Med, Geneva, Switzerland
[2] Univ Geneva, Fac Med, Dept Human Prot Sci, Geneva, Switzerland
来源
PLOS ONE | 2015年 / 10卷 / 04期
基金
瑞士国家科学基金会;
关键词
PROTEIN-COUPLED RECEPTORS; HIGHLY POTENT; ENTRY INHIBITORS; TRAFFICKING; ARRESTIN; RANTES; INTERNALIZATION; IDENTIFICATION; STIMULATION; INFECTIVITY;
D O I
10.1371/journal.pone.0125396
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
G protein-coupled receptors (GPCRs) are desensitized and internalized following activation. They are then subjected to post-endocytic sorting (degradation, slow recycling or fast recycling). The majority of research on post-endocytic sorting has focused on the role of sequence-encoded address structures on receptors. This study focuses on trafficking of CCR5, a GPCR chemokine receptor and the principal entry coreceptor for HIV. Using Chinese Hamster Ovary cells stably expressing CCR5 we show that two different anti-HIV chemokine analogs, PSC-RANTES and 5P14-RANTES, direct receptor trafficking into two distinct subcellular compartments: the trans-Golgi network and the endosome recycling compartment, respectively. Our results indicate that a likely mechanism for ligand-directed sorting of CCR5 involves capacity of the chemokine analogs to elicit the formation of durable complexes of CCR5 and arrestin2 (beta-arrestin-1), with PSC-RANTES eliciting durable association in contrast to 5P14-RANTES, which elicits only transient association.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] TAK-779 - Anti-HIV - Chemokine CCR5 antagonist
    不详
    DRUGS OF THE FUTURE, 2001, 26 (03) : 315 - 317
  • [2] CCR5 antagonists as anti-HIV agents
    不详
    DRUG DISCOVERY TODAY, 2001, 6 (14) : 747 - 747
  • [3] Targeting CCR5 for anti-HIV research
    W.-G. Gu
    X.-Q. Chen
    European Journal of Clinical Microbiology & Infectious Diseases, 2014, 33 : 1881 - 1887
  • [4] Targeting CCR5 for anti-HIV research
    Gu, W. -G.
    Chen, X. -Q.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2014, 33 (11) : 1881 - 1887
  • [5] CCR5 antagonists as anti-HIV agents
    Lloyd, AW
    DRUG DISCOVERY TODAY, 2000, 5 (09) : 428 - 429
  • [6] Synthesis of benzocycloheptene derivatives as CCR5 antagonists with potent anti-HIV activity
    Liu, Yao
    Su, Jing
    Xiao, Jun Hai
    Jiang, Shi Bo
    Lu, Hong
    Zhong, Wu
    Wang, Li Li
    Yang, Xiao Hong
    Li, Song
    CHINESE CHEMICAL LETTERS, 2008, 19 (04) : 428 - 430
  • [8] CENICRIVIROC MESILATE Chemokine CCR2/CCR5 Receptor Antagonist Anti-HIV Agent
    Reviriego, C.
    DRUGS OF THE FUTURE, 2011, 36 (07) : 511 - 517
  • [9] Vicriviroc -: Anti-HIV agent viral entry inhibitor chemokine CCR5 antagonist
    Revill, P.
    Bayes, M.
    Bozzo, J.
    Serradell, N.
    Rosa, E.
    Bolos, J.
    DRUGS OF THE FUTURE, 2007, 32 (05) : 417 - 427
  • [10] Maraviroc -: Anti-HIV agent viral entry inhibitor chemokine CCR5 antagonist
    Ginesta, JB
    Castañer, J
    Bozzo, J
    Bayés, M
    DRUGS OF THE FUTURE, 2005, 30 (05) : 469 - 477